Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2000
11/23/2000CA2368624A1 Novel .beta.-secretase and modulation of .beta.-secretase activity
11/23/2000CA2368593A1 Anti-inflammatory therapy for inflammatory mediated infection
11/22/2000EP1054058A1 Pharmaceutical composition for treatment of Duchenne muscular dystrophy
11/22/2000EP1054007A2 Method for the preparation of (+/-)-calanolide A
11/22/2000EP1053751A1 Compositions and methods for treating cell proliferation disorders
11/22/2000EP1053746A1 Use of biodegradable microspheres for the delivery of a anticancer agent for the treatment of glioblastoma
11/22/2000EP1053745A1 Use of at least a calcium-channel-inhibitor in the treatment of wrinkles
11/22/2000EP1053356A2 Method for diagnosis and treatment of disorders of carbohydrate metabolism
11/22/2000EP1053351A1 Novel molecules of the tnf receptor superfamily and uses therefor
11/22/2000EP1053343A2 Targeting of genetic vaccine vectors
11/22/2000EP1053332A1 Protein
11/22/2000EP1053323A2 Human receptor proteins
11/22/2000EP1053320A2 Human transport-associated molecules
11/22/2000EP1053312A2 Optimization of immunomodulatory properties of genetic vaccines
11/22/2000EP1053255A1 THREE-DIMENSIONAL STRUCTURES AND MODELS OF Fc RECEPTORS AND USES THEREOF
11/22/2000EP1053254A2 COMPOSITIONS AND METHODS TO INHIBIT FORMATION OF THE C5b-9 COMPLEX OF COMPLEMENT
11/22/2000EP1053025A2 Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery
11/22/2000EP1053023A2 Systemic delivery of serum stable plasmid lipid particles for cancer therapy
11/22/2000EP1053022A2 Sensitizing cells to compounds using lipid-mediated gene and compound delivery
11/22/2000EP1053012A1 Pharmaceutical compositions comprising peg-asparaginase for the treatment of hiv infections
11/22/2000EP1053007A2 Methods and compositions for modulating leptin activity
11/22/2000EP1053006A1 Costimulatory blockade and mixed chimerism in transplantation
11/22/2000EP1053003A1 Compositions and methods for separating lens epithelial cells and preventing posterior capsular opacification
11/22/2000EP1052999A1 Chelated 8-hydroxyquinoline for the treatment of epithelial lesions
11/22/2000EP1052998A1 Compositions and methods for modulating cytokine release in response to genotoxic agents
11/22/2000EP1052994A2 Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
11/22/2000EP1052993A1 Combination of an alpha-adrenergic antagonist and a nitrogen oxide donor for treating female sexual dysfunction
11/22/2000EP0701443B2 Terfenadine metabolites and their optically pure isomers for treating allergic disorders
11/22/2000EP0663823B1 Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
11/22/2000CN1274282A Treatment of diabetes with thiazolidinedione and Alpha-glucosidase inhibitor
11/22/2000CN1274281A Compsns. for treating and preventing arterial thrombosis and use of factor Xa inhibitor on its own and/or combined with platelet antiaggegating agent
11/22/2000CN1274280A Delayed total release gastrointestinal drug delivery system
11/22/2000CN1274279A Film-coated tablet for improved upper gastrointestinal tract safety
11/21/2000US6150581 Chitosan/alginate anti-adhesion barrier
11/21/2000US6150530 Amidation of amine with acid
11/21/2000US6150508 Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
11/21/2000US6150418 Propellant-free concentrate suitable for storage containing given concentration of formoterol, or salt or addition products thereof as active substance in a solvent or suspension agent; use in inhalation therapy
11/21/2000US6150401 Use of MEK1 inhibitors as protective agents against damage due to ischemia
11/21/2000US6150398 By administering to a human a synergistic combination of paclitaxel and a dna crosslinking antineoplastic agent, such as cisplatin
11/21/2000US6150395 Indole-3-carbinol (I3C) derivatives and methods
11/21/2000US6150384 Pharmaceutical composition
11/21/2000US6150383 Comprising an insulin sensitivity enhancer in combination with one or more other antidiabetics differing from the enhancer in mechanism of action; lipid/glycometabolism disorders; antidiabetic agents; side effect reduction
11/21/2000US6150349 Methods for treating psychosis associated with glucocorticoid related dysfunction
11/21/2000US6150164 Methods and compositions of a bioartificial kidney suitable for use in vivo or ex vivo
11/21/2000US6150132 Vector coding polypeptides for the diagnosis and treatment of allergies and atherosclerosis; for the prevention of graft ejection and injuries to stem cell caused by anticarcinogenic agents
11/21/2000US6150101 Methods of identifying a composition that alters connective tissue growth factor expression
11/21/2000US6149931 Applying over and around retinal break a non-toxic polymer formulation comprising polymer precursor that is a poly(ethylene glycol) based polymer precursor, and transforming the polymer formulation into a gel-like coat
11/21/2000US6149902 Manipulation of non-terminally differentiated cells using the notch pathway
11/21/2000US6149891 Intravenous injectable mixture comprising radiology contrast agent and a cytoprotective agent which induces cells to generate nitric oxide to protect against damage by contrast agent; side effect reduction
11/21/2000US6149671 Laser/sensitizer assisted immunotherapy
11/21/2000CA2038578C Delivery of agents
11/16/2000WO2000068691A1 Methods for screening gaba-modulatory compounds for specified pharmacological activities
11/16/2000WO2000068687A2 Methods of identifying therapeutic compounds in a genetically defined setting
11/16/2000WO2000068380A2 Extracellular matrix and adhesion-associated proteins
11/16/2000WO2000068243A1 Methods using mechanisms of action of aroa
11/16/2000WO2000068208A1 Pyrimidinones derivatives for the treatment of atherosclerosis
11/16/2000WO2000067847A2 Use of dopamine d3 receptor ligands for producing medicaments for treating kidney disorders
11/16/2000WO2000067802A1 Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
11/16/2000WO2000067798A2 Enhanced delivery of nucleic acid-based drugs
11/16/2000WO2000067796A1 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
11/16/2000WO2000067793A1 Death domain containing receptor 4
11/16/2000WO2000067791A1 Ccr4 antagonists in sepsis
11/16/2000WO2000067780A1 Methods of modulating fabh activity
11/16/2000WO2000067773A2 Combinations of immunosupressive agents for the treatment or prevention of graft rejections
11/16/2000WO2000067739A2 Opioid antagonists containing compositions for enhancing analgesic potency of tramadol and attenuating its adverse side effects
11/16/2000WO2000067738A2 The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders
11/16/2000WO2000067736A2 Therapeutic use of an inhibitor or an antagonist of an abc protein in bone
11/16/2000WO2000067735A2 USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION
11/16/2000WO2000067732A2 Pharmaceutical composition, containing an antimycotic, polydocanol and salicylic acid
11/16/2000WO2000067730A1 Drug delivery device
11/16/2000WO2000067592A1 Methods for lowering viscosity of glucomannan compositions
11/16/2000WO2000067576A1 Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
11/16/2000WO2000043501A3 Ribozymes directed against the catalytic subunit of the human telomerase (htert)
11/16/2000WO2000039287A3 A. fumigatus acetyl coenzyme-a carboxylase genes and polypeptides and uses thereof
11/16/2000WO2000038665A3 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
11/16/2000WO2000038625A3 Facial tissue composition and method of use for sequestration of nasal secretion skin irritants
11/16/2000WO2000038536A3 Inhibitors of the bitter taste response
11/16/2000WO2000037639A3 Lymphocytic membrane proteins
11/16/2000WO2000034511A3 Aβ-PEPTIDE SCREENING ASSAY
11/16/2000WO2000034468A3 Muc-1 antagonists and methods of treating immune disorders
11/16/2000WO2000033825A3 Compositions and methods for amelioration of human female sexual dysfunction
11/16/2000WO2000032186A3 Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
11/16/2000WO2000029015A3 INFLUENCING OF ANGIGENESIS USING CD66a
11/16/2000WO2000026370A3 Adenine nucleotide translocator (ant) fusion proteins and uses thereof
11/16/2000WO2000023466A3 Human rna binding proteins
11/16/2000WO2000018365A3 Fast dissolving orally consumable films
11/16/2000WO2000018316A3 Sustained release, and comfortable ophthalmic composition and method for ocular therapy
11/16/2000WO2000009549A3 Peripheral-type benzodiazepine receptor associated proteins, cloning, expression and methods of use
11/16/2000WO2000007543A8 Conjugates targeted to the interleukin-2 receptors
11/16/2000WO2000006138A3 Use of moclobemide for treating pain and other diseases
11/16/2000WO2000005375A9 Gbs toxin receptor
11/16/2000WO2000001713A3 Diacylglycerol acyl transferase proteins
11/16/2000WO1999051186A3 Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
11/16/2000DE19921693A1 Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
11/16/2000DE19920247A1 Arzneimittel mit einem Gehalt an Verbindungen mit einem Stickstoff-Sauerstoff-Heterocyclus als Wirkstoff und ihre Verwendung Medicaments with an amount of compounds having a nitrogen-oxygen heterocycle as active ingredient and their use
11/16/2000DE10021266A1 Hergestellte Artikel mit Phosphodiesterase-Inhibitor Produced with Article phosphodiesterase inhibitor
11/16/2000CA2384338A1 Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
11/16/2000CA2373550A1 Methods of identifying therapeutic compounds in a genetically defined setting
11/16/2000CA2373348A1 Opioid antagonists containing compositions for enhancing analgesic potency of tramadol and attenuating its adverse side effects
11/16/2000CA2373178A1 The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders
1 ... 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 ... 1151